BridgeBio's heart drug Attruby exceeds sales expectations, shifting investor outlook
BridgeBio prepared to sell its heart drug Attruby on its own, prompting skepticism from investors and analysts who doubted the company could compete with larger rivals.
The drug far outperformed forecasts, generating $362 million in revenue in 2025 compared with the $100 million analysts had hoped for.
The unexpected success has flipped analyst commentary, with the company now hearing more positive notes than the earlier doubts.
This example illustrates a growing trend of young biotech firms launching their own products profitably, which could make the sector more attractive to investors.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that